Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Phase 1 clinical trial for SSAO/VAP-1 inhibitor commences

Pharmaxis today announced that it has commenced a Phase 1 clinical trial of  its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) investigating its potential to treat inflammatory diseases.

Phase 3 clinical trial in cystic fibrosis begins

Pharmaxis has enrolled the first subject in its international clinical trial evaluating Bronchitol® in adults with cystic fibrosis (CF303).

Significant business milestones: Commercialisation of Bronchitol (Mannitol) in USA, Novaquest dispute settled

Pharmaxis announced it has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) in the United States.

Pharmaxis signs agreement with Boehringer Ingelheim for SSA Inhibitor PXS4728A

Pharmaxis has announced it has signed an Option and Asset Purchase Agreement with Boehringer Ingelheim for the SSAO Inhibitor PXS4728A.